Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia

Molecular Brain Research

Volumn 56, Issue 1-2, 1998, Pages 207-217

  Ohnuma, Tohru ^a,b   Augood, Sarah J ^b   Arai, Heii ^a   McKenna, Peter J ^c   Emson, Piers C ^b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Lab of Molec and Cogn Neurosci   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Excitatory amino acid; Glutamate; Glutamate transporter; In situ hybridization; Metabotropic glutamate receptor; Schizophrenia

Indexed keywords

CARRIER PROTEIN; EXCITATORY AMINO ACID; GLUTAMIC ACID; MESSENGER RNA; METABOTROPIC RECEPTOR;

AGED; AMINO ACID TRANSPORT; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; OPTICAL DENSITY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PYRAMIDAL TRACT; SCHIZOPHRENIA;

AGED; AGED, 80 AND OVER; EXCITATORY AMINO ACID TRANSPORTER 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PREFRONTAL CORTEX; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, NEUROTRANSMITTER; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 0032078391     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(98)00063-1     Document Type: Article

References (60)

1. 2+ signal transduction. J. Biol. Chem. 267:1992;13361-13368.
2. Ariel R.N., Golden C.J., Berg R.A., Quaife M.A., Dirksen J.W., Forsell T., Wilson J., Graber B. Regional cerebral blood flow in schizophrenics: tests using the xenon Xe 133 inhalation method. Arch. Gen. Psychiatry. 40:1983;258-263.
3. Arriza J.L., Fairman W.A., Wadiche J.I., Murdoch G.H., Kavanaugh M.P., Amara S.G. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J. Neurosci. 14:1994;5559-5569.
4. Augood S.J., Faull R.L., Love D.R., Emson P.C. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience. 72:1996;1023-1036.
5. Browning M.D., Dudek E.M., Rapier J.L., Leonard S., Freedman R. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biol. Psychiatry. 34:1993;529-535.
6. Buchsbaum M.S., Nuechterlein K.H., Haier R.J., Wu J., Sicotte N., Hazlett E., Asarnow R., Potkin S., Guich S. Glucose metabolic rate in normals and schizophrenics during the Continuous Performance Test assessed by positron emission tomography. Br. J. Psychiatry. 156:1990;216-227.
7. Choe B.Y., Suh T.S., Shinn K.S., Lee C.W., Lee C., Paik I.H. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest. Radiol. 31:1996;345-352.
8. Daly D.A., Moghaddam B. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci. Lett. 152:1993;61-64.
9. Deakin J.F., Slater P., Simpson M.D., Gilchrist A.C., Skan W.J., Royston M.C., Reynolds G.P., Cross A.J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 52:1989;1781-1786.
10. Divac I., Fonnum F., Storm-Mathisen J. High affinity uptake of glutamate in terminals of corticostriatal axons. Nature. 266:1977;377-378.
11. Eastwood S.L., Harrison P.J. Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography. Neuroscience. 69:1995;339-343.
12. Eastwood S.L., Burnet P.W., Harrison P.J. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience. 66:1995;309-319.
13. Fairman W.A., Vandenberg R.J., Arriza J.L., Kavanaugh M.P., Amara S.G. An excitatory amino acid transporter with properties of a ligand-gated chloride channel. Nature. 375:1995;599-603.
14. Fonnum F. Regulation of the synthesis of the transmitter glutamate pool. Prog. Biophys. Mol. Biol. 60:1993;47-57.
15. Gegelashvili G., Civenni G., Racagni G., Danbolt N.C., Schousboe I., Schousboe A. Glutamate receptor agonists up-regulate glutamate transporter GLAST in astrocytes. NeuroReport. 8:1996;261-265.
16. Godukhin O.V., Zharikova A.D., Novoselov V.I. The release of labelled L-glutamic acid from rat neostriatum in vivo following stimulation of frontal cortex. Neuroscience. 5:1980;2151-2154.
17. Halberstadt A.L. The phencyclidine-glutamate model of schizophrenia. Clin. Neuropharmacol. 18:1995;237-249.
18. 2 receptor, proenkephalin A and substance P gene expression in the caudate nucleus of control and schizophrenic tissue: a quantitative cellular in situ hybridization study. Brain Res. Mol. Brain Res. 33:1995;333-342.
19. Harrison P.J., Procter A.W., Barton A.J., Lowe S.L., Najlerahim A., Bertolucci P.H., Bowen D.M., Pearson R.C. Terminal coma affects messenger RNA detection in postmortem human temporal cortex. Brain Res. Mol. Brain Res. 9:1991;161-164.
20. Houamed K.M., Kuijper J.L., Gilbert T.L., Haldeman B.A., O'Hara P.J., Mulvihill E.R., Almers W., Hagen F.S. Cloning, expression, and gene structure of a G protein-coupled glutamate receptor from rat brain. Science. 252:1991;1318-1321.
21. Ingvar D.H., Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta. Psychiatr. Scand. 50:1974;425-462.
22. Ishimaru M., Kurumaji A., Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol. Psychiatry. 35:1994;84-95.
23. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatry. 9:1987;12-35.
24. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
25. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry. 151:1994;1234-1236.
26. Johnson S.A., Morgan D.G., Finch C.E. Extensive postmortem stability of RNA from rat and human brain. J. Neurosci. Res. 16:1986;267-280.
27. Kendrick K.M., Guevara-Guzman R., de la Riva C., Christensen J., Ostergaard K., Emson P.C. NMDA and kainate-evoked release of nitric oxide and classical transmitters in the rat striatum: in vivo evidence that nitric oxide may play a neuroprotective role. Eur. J. Neurosci. 8:1996;2619-2634.
28. Kim J.S., Hasller R., Hau P., Paik K.S. Effect of frontal cortex ablation on striatal glutamic acid level in rat. Brain Res. 132:1977;370-374.
29. Kiryu S., Yao G.L., Morita N., Kato H., Kiyama H. Nerve injury enhances rat neuronal glutamate transporter expression: identification by differential display PCR. J. Neurosci. 15:1995;7872-7878.
30. 3H ]MK-801 binding sites in postmortem brain regions of schizophrenic patients J. Neural Transm. 77:1989;231-236.
31. Korpi E.R., Kleinman J.E., Goodman S.I., Wyatt R.J. Neurotransmitter amino acids in postmortem brains of chronic schizophrenic patients. Psychiatry Res. 22:1987;291-301.
32. Lee T., Seeman P. Abnormal neuroleptic/dopamine receptors in schizophrenia. Adv. Biochem. Psychopharmacol. 21:1980;435-442.
33. Lee T., Seeman P. Elevation of brain neuroleptic/dopamine receptors in schizophrenia. Am. J. Psychiatry. 137:1980;191-197.
34. 3H -apomorphine in schizophrenic brains Nature. 274:1978;897-900.
35. Makoff A., Volpe F., Lelchuk R., Harrington K., Emson P. Molecular characterization and localization of human metabotropic glutamate receptor type 3. Brain Res. Mol. Brain Res. 40:1996;55-63.
36. Masu M., Tanabe Y., Tsuchida K., Shigemoto R., Nakanishi S. Sequence and expression of a metabotropic glutamate receptor. Nature. 349:1991;760-765.
37. Minakami R., Katsuki F., Yamamoto T., Nakamura K., Sugiyama H. Molecular cloning and the functional expression of two isoforms of human metabotropic glutamate receptor subtype 5. Biochem. Biophys. Res. Commun. 199:1994;1136-1143.
38. Nakajima Y., Iwakabe H., Akazawa C., Nawa H., Shigemoto R., Mizuno N., Nakanishi S. Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate. J. Biol. Chem. 268:1993;11868-11873.
39. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science. 258:1992;597-603.
40. 3H ]kainic acid binding in the prefrontal cortex in schizophrenia Neurosci. Lett. 40:1983;245-250.
41. Okamoto N., Hori S., Akazawa C., Hayashi Y., Shigemoto R., Mizuno N., Nakanishi S. Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. J. Biol. Chem. 269:1994;1231-1236.
42. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
43. Oretti R.G., Spurlock G., Buckland P.R., McGuffin P. Lack of effect of antipsychotic and antidepressant drugs on glutamate receptor mRNA levels in rat brains. Neurosci. Lett. 177:1994;39-43.
44. Owen F., Cross A.J., Crow T.J., Longden A., Poulter M., Riley G.J. Increased dopamine-receptor sensitivity in schizophrenia. Lancet. 2:1978;223-226.
45. S.G. Potkin, J. Costa, S. Roy, J. Sramek, Y. Jin, B. Gulasekaran, Glycine in the treatment of schizophrenia: theory and preliminary results, in: H.Y. Meltzer, (Ed.), Novel Antipsychotic Drugs, Raven Press, New York, 1992, pp. 179-188.
46. Reisine T.D., Rossor M., Spokes E., Iversen L.L., Yamamura H.I. Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue. Adv. Biochem. Psychopharmacol. 21:1980;443-450.
47. Saugstad J.A., Kinzie J.M., Mulvihill E.R., Segerson T.P., Westbrook G.L. Cloning and expression of a new member of the L-2-amino-4-phosphonobutyric acid-sensitive class of metabotropic glutamate receptors. Mol. Pharmacol. 45:1994;367-372.
48. Schoepp D.D., Johnson B.G. Metabotropic glutamate receptor modulation of cAMP accumulation in the neonatal rat hippocampus. Neuropharmacology. 32:1993;1359-1365.
49. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1:1987;133-152.
50. Sherman A.D., Davidson A.T., Baruah S., Hegwood T.S., Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci. Lett. 121:1991;77-80.
51. Sherman A.D., Hegwood T.S., Baruah S., Waziri R. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. Biol. Psychiatry. 30:1991;1191-1198.
52. Simpson M.D., Slater P., Royston M.C., Deakin J.F. Alterations in phencyclidine and sigma binding sites in schizophrenic brains: effects of disease process and neuroleptic medication. Schizophr. Res. 6:1991;41-48.
53. Sladeczek F., Pin J.P., Recasens M., Bockaert J., Weiss S. Glutamate stimulates inositol phosphate formation in striatal neurons. Nature. 317:1985;717-719.
54. Tanabe Y., Masu M., Ishii T., Shigemoto R., Nakanishi S. A family of metabotropic glutamate receptors. Neuron. 8:1992;169-179.
55. Thierry A.M., Tassin J.P., Blanc G., Glowinski J. Selective activation of mesocortical DA system by stress. Nature. 263:1976;242-244.
56. Toru M., Watanabe S., Shibuya H., Nishikawa T., Noda K., Mitsushio H., Ichikawa H., Kurumaji A., Takashima M., Mataga N., Ogawa A. Neurotransmitters, receptors and neuropeptides in postmortem brains of chronic schizophrenic patients. Acta. Psychiatr. Scand. 78:1988;121-137.
57. Toru M., Kurumaji A., Ishimaru M. Excitatory amino acids: implications for psychiatric disorders research. Life Sci. 55:1994;1683-1699.
58. Waziri R. Glycine therapy of schizophrenia. Biol. Psychiatry. 23:1988;210-211.
59. Weinberger D.R., Berman K.F., Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatry. 43:1986;114-124.
60. Yamamoto B.K., Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14:1994;4159-4166.